NO donors may be similarly useful in the treatment of other cancers by targeting the underlying HIF-1α-mediated chemotherapy resistance, although no active clinical trials that test the effectiveness of adding a NO donor alone to chemotherapy are underway [225]. The gene discussed is HIF1A; the disease is cancer.